文献速递前列腺癌

局限性前列腺癌局灶放疗的系统综述:临床证据与结局

Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-11-04

该PRISMA系统综述检索Pubmed至2025年2月,评估局灶或部分腺体放疗对局限性前列腺癌的肿瘤学与毒性结局。局灶近距离放疗和部分腺体SBRT对毒性及生活质量影响轻微,仅6-12个月尿频一过性增加后恢复基线;在高选择的低危和中危患者中5年生化无复发生存率达97%、无转移生存率达100%。

要点

  • 局灶放疗毒性低,仅6-12个月尿频一过性增加后恢复基线。
  • 高选择低/中危患者5年bRFS达97%、MFS达100%。
  • 腺内复发多为野外,可局灶治疗或根治性前列腺切除挽救。

核心结论

  • 局灶放疗毒性低且肿瘤学结局优异。
  • 多数研究纳入低危或有利中危、适合主动监测的患者。
  • 期待正在进行的针对不适合主动监测的中危患者及采用先进影像靶区定义的研究结果。

研究设计与样本

  • 系统综述,遵循PRISMA指南。
  • 2025年2月在Pubmed检索,关键词包括「focal RT」「definitive」「prostate cancer」及「focal brachytherapy」「definitive」「prostate cancer」。

主要发现

  • 局灶近距离放疗和部分腺体SBRT对毒性和生活质量参数影响极小。
  • 仅提示局灶治疗后6-12个月尿频一过性增加,之后恢复基线。
  • 在高选择的低危和中危前列腺癌患者中(具备优良放射-组织学一致性且阳性针数有限),局灶放疗显示优异的生化无复发生存和无转移生存,5年分别达97%和100%。
  • 后续腺内复发多发生在照射野外,可通过局灶治疗或根治性前列腺切除术挽救,无严重毒性风险增加的信号。

临床怎么用

  • 局灶放疗可用于高选择的低危或有利中危局限性前列腺癌患者。
  • 治疗前应确认放射-组织学一致性好且阳性针数有限。
  • 腺内复发后可根据情况选择局灶治疗或根治性前列腺切除术挽救。

局限性

  • 多数研究纳入低危或有利中危患者,包括适合主动监测者。
  • 缺乏针对不适合主动监测的中危患者及采用先进影像定义靶区的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advances in imaging modalities and radiotherapy (RT) technologies have enabled the development of focal RT approaches for localized prostate cancer (PCa). This systematic review aims to evaluate the oncological and toxicity outcomes of focal or partial-gland RT, while also discussing the optimal patient selection criteria and treatment planning strategies for this emerging approach. METHODS: This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The literature search was performed on February, 2025, on Pubmed, with the keywords "focal RT" and "definitive" and "prostate cancer"; and "focal brachytherapy (BT)" and "definitive" and "prostate cancer". RESULTS: Both focal BT and partial-gland stereotactic body radiotherapy (SBRT) strategies demonstrated a minimal impact on toxicity and quality of life parameters. Only a transient increase in urinary frequency was suggested at 6-12 months following focal treatment, returning to baseline thereafter. In highly selected low-risk (LR) and intermediate-risk (IR) PCa patients with both excellent radiological-histological concordance and a limited number of positive cores, focal RT demonstrated excellent biochemical relapse-free survival and metastasis-free survival, reaching up to 97% and 100% at 5 years. Subsequent intraprostatic relapse mostly occurred out-of-field, and were salvaged with either focal treatment or radical prostatectomy, with no signal of increased risk of severe toxicity. CONCLUSION: Focal RT is associated with low toxicity rates, and excellent oncological outcomes. However, most studies recruited LR or favorable IR PCa, including patients eligible for active surveillance. Results from ongoing and future studies evaluating focal RT in IR PCa patients not eligible for active surveillance, and incorporating advanced imaging for target volume definition are eagerly awaited.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Le Guévelou J, Peyrottes A, Barret E, et al. Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes. Prostate Cancer Prostatic Dis. 2025. PMID: 41188543. doi:10.1038/s41391-025-01050-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。